Ex-BMS exec to lead immuno-oncology play Kleo

Immuno-oncology company Kleo Pharmaceuticals Inc. (New Haven, Conn.) named Doug Manion CEO. The Yale University spinout is developing two synthetic small molecule platforms designed to mimic an antibody's role in activating the immune system against cancer cells.

Manion was SVP and head of specialty development at Bristol-Myers Squibb Co. (NYSE:BMY). Kleo co-founder David Spiegel, who had been CEO since September 2016, will become the company's president...